Eventide Asset Management’s ADC Therapeutics ADCT Stock Holding History

Eventide Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.4M	Buy	5,701,655 +2,337,588	+69%	+$9.22M	0.35%	100
2025 Q4	$11.9M	Buy	+3,364,067	New	+$13.7M	0.19%	134
2023 Q2	–	Sell	-1,675,959	Closed	-$3.27M	–	140
2023 Q1	$3.27M	Sell	1,675,959 -204,000	-11%	-$753K	0.06%	131
2022 Q4	$7.22M	Hold	1,879,959	–	–	0.14%	119
2022 Q3	$9.06M	Hold	1,879,959	–	–	0.18%	106
2022 Q2	$14.9M	Sell	1,879,959 -95,041	-5%	-$899K	0.32%	81
2022 Q1	$29M	Hold	1,975,000	–	–	0.45%	67
2021 Q4	$39.9M	Buy	1,975,000 +663,010	+51%	+$16M	0.51%	68
2021 Q3	$35.6M	Hold	1,311,990	–	–	0.47%	69
2021 Q2	$31.9M	Buy	1,311,990 +397,251	+43%	+$9.22M	0.43%	70
2021 Q1	$22.3M	Sell	914,739 -160,261	-15%	-$4.64M	0.33%	89
2020 Q4	$34.4M	Buy	1,075,000 +494,517	+85%	+$16.2M	0.53%	62
2020 Q3	$19.1M	Buy	580,483 +430,483	+287%	+$18.6M	0.37%	77
2020 Q2	$7.02M	Buy	+150,000	New	+$5.69M	0.15%	100

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eventide Asset Management's ADCT Position: Q1 2026 in Review

Eventide Asset Management increased its ADC Therapeutics (ADCT) stake by 69% in Q1 2026, buying an estimated $9.22M and bringing the position to 5,701,655 shares worth $21.4M. The position accounts for 0.35% of the portfolio, ranked #100.

Eventide Asset Management first reported a position in ADCT in Q2 2020 and has held it in 14 quarters since. The position peaked at $39.9M in Q4 2021. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Eventide Asset Management held 5,701,655 shares of ADC Therapeutics worth $21.4M as of Q1 2026.
Eventide Asset Management bought 2,337,588 ADC Therapeutics shares in Q1 2026, an estimated $9.22M.
ADC Therapeutics made up 0.35% of Eventide Asset Management's portfolio in Q1 2026, its #100 holding.
Eventide Asset Management first reported a position in ADC Therapeutics in Q2 2020 and has held it in 14 quarters since.
Eventide Asset Management's ADC Therapeutics position peaked at $39.9M in Q4 2021.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.